Neuropathic pain is a debilitating condition resulting from damage to sensory transmission pathways in the peripheral and central nervous system. A potential new way of treating chronic neuropathic pain is to target specific pain-processing neurons based on their expression of particular receptor molecules. We hypothesized that a toxin-neuropeptide conjugate would alter pain by first being taken up by specific receptors for the neuropeptide expressed on the neuronal cells. Then, once inside the cell the toxin would inhibit the neurons' activity without killing the neurons, thereby providing pain relief without lesioning the nervous system. In an effort to inactivate the nociceptive neurons in the trigeminal nucleus caudalis in mice, we targeted the NK1 receptor (NK1R) using substance P (SP). The catalytically active light chain of botulinum neurotoxin type A (LC/A) was conjugated with SP. Our results indicate that the conjugate BoNT/A-LC:SP is internalized in cultured NK1R-expressing neurons and also cleaves the target of botulinum toxin, a component-docking motif necessary for release of neurotransmitters called SNAP-25. The conjugate was next tested in a murine model of Taxol-induced neuropathic pain. An intracisternal injection of BoNT/A-LC:SP decreased thermal hyperalgesia as measured by the operant orofacial nociception assay. These findings indicate that conjugates of the light chain of botulinum toxin are extremely promising agents for use in suppressing neuronal activity for extended time periods, and that BoNT/A-LC:SP may be a useful agent for treating chronic pain. Ó
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Introduction
Neuropathic pain syndromes such as diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia and chemotherapy induced neuropathy lack consistently effective therapies [16] . The exact mechanism of neuropathic pain is unknown. Neuropathic pain signals, whether arising from an axonal site on primary sensory neurons or from extra-junctional sites, are transmitted to the spinal dorsal horn or trigeminal nucleus caudalis [42], frequently leading to central sensitization, which is symptomatically expressed as allodynia, and hyperalgesia [11] . Among the various neurotransmitter receptors, the neurokinin 1 receptor (NK1R) plays an important role in the transmission of neuropathic pain. The role of NKR1 in neuropathic pain is supported by the ability of NKR1 antagonists to suppress pain in a chronic constriction injury model [6] . NK1Rs are widespread in nociceptive pathways in the central nervous system, and the ablation of spinal NK1R-expressing neurons is an effective strategy to reduce most types of pain. Previous research has demonstrated that delivering Saporin, a ribosome-inactivating neurotoxin, conjugated with SP (SP-SAP) can selectively kill NK1R-expressing cells. This lesion results in attenuation of hyperalgesia and allodynia by interrupting the nociceptive pathway [22, 23, 29, 40] . On the basis of this principle, a variety of lethal toxins such as diphtheria and pseudomonas exotoxin were conjugated with SP by various groups as potential therapeutics [3, 4] . Also, a non-lethal cholera toxin and SP conjugate has also been reported to selectively activate NK1R-expressing neurons producing allodynia and hyperalgesia [8] [9] [10] . Thus delivering targeted toxins to NK1R expressing cells is a useful means of manipulating pain.
Botulinum neurotoxin (BoNT) is the most potent among the clostridial neurotoxins and is expressed as 7 serologically distinct types (BoNT/A-F) [35] . Among these, BoNT/A (serotype A) is considered to have more sustained action because of its ability to
